Application of isoosmotic ionic sea water-based solutions for manufacturing medical devices applied for preventing development of complications of rhinitis or influenza-like syndrome

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to a method of preventing complications of rhinitis or an influenza-like syndrome. The method of preventing complications of rhinitis or the influenza-like syndrome consists in the following: an isoosmotic ionic sea water-based solution with osmolarity, equal to 250-350 mOsm/kg, is introduced daily into each nostril of patients suffering from rhinitis or the influenza-like syndrome, and at the remission stage in the certain regimens.

EFFECT: increased method efficiency.

9 cl, 13 dwg, 13 tbl, 1 ex

 

This invention relates to the use of isoosmotic ionic solutions on the basis of sea water for the manufacture of medical devices to prevent complications from a cold or flu-like syndrome.

According to this invention, the term "isoosmotic ionic solution or the composition of sea water-based" refers to any solution based on sea water, namely the solution or composition containing more than 30% by weight of sea water, preferably more than 75% by weight of sea water, which are osmotolerant equal 250-350 mOsm/kg, preferably equal 305-315 OSM/kg This definition does not cover the so-called physiological solutions, which contain only ions such as Na and Cl, and possibly Se ions.

The applicant has already described the use of isoosmotic ionic solutions on the basis of seawater to prevent and limit the release of chemical mediators that are responsible for triggering inflammation in the mucous membrane of the bronchi and lungs, in particular described in patent EP 1091747, and also for putting in the ear canal to soften sulfur that described in the patent EP 1091746.

In addition, the applicant has created ion solutions on the basis of water, of the type described in this application, which are rich in potassium, for treatment and irrigation of the eyes and to use the project as a product for rinsing contact lenses. These solutions and their application are described in particular in patents FR 2843029 and FR 2803205.

Rhinitis is the most common contagious and infectious viral disease that occurs in humans. On average, adults suffer from a cold two to four times per year, and in children runny nose sometimes up to twelve times a year. Runny nose accompanied with naselenie symptoms like burning sensation in the nose, sneezing, expiration nose in varying degrees and the feeling of nasal congestion and a sore throat, temperature and discomfort, which can lead to absenteeism. A runny nose is a rhinoviral disease capable of spontaneous remission in about a week after the beginning, and is accompanied by a residual cough that can last up to three weeks. Patients suffering from flu-like syndrome, have similar symptoms, although in this case there is a different family of viruses.

According to this invention, the term "patients suffering from a cold or flu-like syndrome refers to patients with symptoms observed in the first week of cold, and the term "patients in remission" refers to patients who have a residual cough.

Due to the General condition of the patient during these diseases, it is less resistant to bacteria. Following the journey of this in patients in remission cold or flu-like syndrome or patients suffering from a cold or flu-like syndrome, frequently observed complications. According to this invention, the term "complication of the common cold or flu-like syndrome" refers to bacterial infections of the throat, bronchi, rhinopharyngitis, ear and sinus infections. These complications may require antibiotics. In addition, treatment of common cold or influenza-like syndrome is often accompanied by the use of anti-inflammatory drugs, anti-infective agents, antipyretics, mucolytics are presented, funds from nasal congestion and cough remedies.

However, prolonged use of such treatment leads to the appearance of side effects and/or the patient no longer tolerate this treatment.

Therefore, there is indeed a need to create a product that is well tolerated in long-term treatment, causes no side effects and enables to prevent any complication from a cold or flu-like syndrome while reducing or eliminating the use of conventional medicines, such as, in particular, anti-inflammatories, antipyretics, anti-infective assets, nasal congestion and cough.

The applicant has unexpectedly found that daily administration of nasal spray or aerosol and osmoticheskogo ion solution on the basis of seawater at the time of development of fever or flu-like syndrome or after this episode of common cold or influenza-like syndrome enables to prevent complications to prevent relapses, reduce the number and frequency of occurrence of rhinitis and faster to improve the overall health of patients while eliminating the use of medical devices.

Thus, the present invention relates to the use of isoosmotic ionic solutions on the basis of sea water for the manufacture of medical devices for the introduction of the specified solution in a nasal spray or aerosol for patients in remission cold or flu-like syndrome or patients suffering from a cold or flu-like syndrome, prevention or treatment of complications from a cold or flu-like syndrome.

According to this invention the medical device is a container, equipped with a tube for nasal spray or aerosol containing the specified isoosmotic solution on the basis of sea water.

This invention provides for the treatment of both adults and children and babies. According to one preferred variant, when the patient is an adult, the solution is applied in the form of a nasal spray. When the patient is a child or infant, it is preferable to apply a spray for the nose.

In this application the number of daily injections, sprays or aerosols are specified for each nasal cavity.

Over oncrete, isoosmotic ionic solution on the basis of sea water is:

- pH 7,8-8,4;

the dry matter content equal to from 1 to 2% by weight;

- osmolarity equal to 250-350 mOsm/kg, preferably equal 305-315 mOsm/kg,

and contains the following main components:

- 500-2600 mg/l sodium (Na);

- 40-6500 mg/l potassium (Ka);

- 5800-6000 mg/l of chlorine ions (Cl);

- 20-400 mg/l calcium (CA);

- 50-1500 mg/l magnesium (Mg).

According to the first preimushestvennogo option isoosmotic ionic solution on the basis of sea water is:

- pH 7,8-8,4;

the dry matter content equal to from 1 to 2% by weight;

- osmolarity equal 305-315 mOsm/kg, and contains the following main chemical components:

- 2000-2600 mg/l sodium (Na);

40-80 mg/l potassium (Ka);

- 5800-6000 mg/l of chlorine ions (Cl);

- 300-400 mg/l calcium (CA);

- 1200-1500 mg/l magnesium (Mg).

According to the second preimushestvennogo option isoosmotic ionic solution on the basis of sea water is:

- pH 7,0-9,0;

the dry matter content equal to from 1 to 2% by weight;

- osmolarity equal to 250-350 mOsm/kg, and contains the following main chemical components:

- 500-1500 mg/l sodium, preferably 1000-1300 mg/l sodium (Na);

- 4500-6500 mg/l potassium, preferably 5000-6500 mg/l (Ka);

- 50-1300 mg/l magnesium, preferably 100-500 mg/l magnesium (Mg);

- 4000-6000 mg/l of chlorine ions, preferably 4500-5000 the g/l chloride ions (Cl);

- 20-350 mg/l calcium, preferably 40-200 mg/l calcium (CA).

The solution is based on sea water, such as used according to the invention can be sterile or may be sterilized.

Preferably, the solution is based on sea water also contained other elements such as bromine (Br), preferably in a quantity of 50 mg/l, aluminum (Al), fluorine (F)iodine (I), iron (Fe), zinc (Zn), copper (Cu), manganese (Mn), selenium (Se).

Very preferably, the composition contains elements that differ from sodium, potassium, chloride ions, calcium and magnesium, was identical to seawater qualitatively and quantitatively.

As regards the quantitative ratio, the composition of the ionic composition of the solutions used according to the invention, identical to the composition of sea water.

To illustrate, below is a table which shows the composition of sea water is given in " Handbook of Chemistry and Physics, 63rd edition, 1982-1983, p. F 163, CRC PRESS.

Ti
Table a
Amount (ppm)
Cl18,980
Na10,561
Mg 1,272
S884
CA400
To380
Br65
With (neorganic.)28
Sr13
(SiO2)0,01-7,0
In4,6
Siof 0.02 to 4.0
With (organic.)1,2-3,0
Al0,16-1,9
F1,4
N (nitrate)0,01-0,7
N (organic. nitrogen)0,03-0,2
Rb0,2
Li0,1
P (phosphate)>0.001-0,10
VA0,05
I0,05
N (nitrite)0,0001
N (ammonium)>0,005-0, 05
As (arsenic)0,003-0,024
Fe0,002-0,02
P (organic. phosphorus)0,016
Znof 0,005 0,014
Cu0,001-0,09
Mn0,001-0,01
Pb0,004-0,005
Se0,004
Sn0,003
Cs0,002 (about)
U0,00015-0,0016
Mo 0,0003-0,002
Ga0,0005
Ni0,0001-0,0005
Th<0,0005
Ce0,0004
V0,0003
La0,0003
Y0,0003
Hg0,00003
Ag0,00015-0,0003
Biis 0.0002
Co0,0001
Sc0,00004
Au0,000004-0,000008
Fe (true solution)<10-9
Ra2.10-11-3.10-10
Gecontains
contains
Wcontains
Cdfound in marine organisms
Crfound in marine organisms
Tlfound in marine organisms
Sbfound in marine organisms
Zrfound in marine organisms
Ptfound in marine organisms

On the same page of this publication indicates that the pH of sea water equal to 8-9.

It is also known (IFREMER, Coastal Environment and Marine Environment Management Department)that the osmolarity of sea water is more than 1000 mOsm/kg

It is also known that in raw seawater ratio of Na:Mg is equal to more than 8.

Below presents data reflecting the results of 134 measurements of samples of sea water in Saint-Malo, made in the period from August 1998 to July 1999:

pH: 7,70-8, 30;

osmolarity: >1000 mOsm/kg;

(Na4): 10500-11500 mg/l;

(K+): 365-420 mg / l;

(g ++): 1200-1450 mg/l;

(CA++): 380-435 mg/l;

(CL-): 18900-20500 mg/l;

the ratio of Na:Mg:>8.

Ionic solutions used according to the invention do not contain any preservatives or stabilizers. This is a very important advantage.

In fact, preservatives or stabilizers contained in most synthetic ionic aqueous solutions cause side effects to a greater or lesser extent in a long time. However, according to this invention the ionic solution is used for periods of time lasting from two weeks to several months or even years.

The present invention relates also to the use of isoosmotic ionic solution based on sea water for preparation of a medical product for insertion into a nasal spray or aerosol for patients suffering from a cold or flu-like syndrome, or patients in remission cold or flu-like syndrome prevention or treatment of complications from a cold or flu-like syndrome.

Specified medical product may contain pharmaceutically acceptable carriers in addition to ion solution on the basis of sea water. Preferably, the medical product does not contain preservatives or stabilizers.

In accordance with one pre is respectful variant of the invention, patients in remission cold or flu-like syndrome solution is injected daily, and more preferably, three times per day in the absence of a cold or flu-like syndrome, for at least one week, preferably for at least two weeks.

In accordance with another preferred variant of the invention to patients suffering from a cold or flu-like syndrome, the solution is injected from two to nine times, preferably from three to eight times, more preferably four to six times daily during an episode of fever or influenza-like syndrome, and remission is administered from one to three times daily for at least two weeks, with the dose reduced in remission.

Considering the fact that isoosmotic ionic solution used according to the invention, does not cause side effects associated, in particular, with the presence of stabilizers, this solution can be used daily for a whole year, preferably during epidemics.

This invention relates also to the use described above, when the specified solution is injected during an episode of cold or flu-like syndrome without the use of any other medicines or treatment stage or at the stage of prevention, that is, not in the treatment of cold or flu-like syndrome or for the settlement of EBUSY weeks. Thus, patients in remission cold or flu-like syndrome or patients suffering from a cold or flu-like syndrome, can be treated without the use of any of the agents selected from the group comprising antibiotics, antipyretic, mukoliticeski agent, anti-inflammatory, anti-infective agent, remedy for nasal congestion, cough medicine, and mixtures thereof.

Unexpectedly, it was found that isoosmotic ionic solutions used according to the invention, tolerated very well by patients who complained of a burning sensation at the time of their application, especially when used in a nasal spray. In addition, the tolerability of the product was increased over time.

In accordance with the preferred regimen solution is injected daily for years, in the form of at least spray or aerosol, at least once a day, at least twice a day, preferably at least three times a day and, more preferably, at least six times a day, in the form of a spray or aerosol during epidemiological episodes of common cold or influenza-like syndrome.

Particularly preferably, if you gain isoosmotic ionic solutions used according to the invention, by electrodialysis of sea water. More specifically, e is from the method is as follows:

as the initial substance use sea water with a salt content of equal to or greater than 32 g/l, the samples which are taken mostly at depths of 5 to 10 m in areas with strong current,

- specified water analyze and defend,

from distilled water to remove sodium by electrodialysis up until the osmolarity becomes equal 250-350 mOsm/kg, preferably 305-315 mOsm /kg,

- regulate the concentration of ions through selective electrodialysis,

- the resulting product is filtered and stored, perhaps in a sterile environment.

The application of this method makes it possible to adjust the ion concentration of the main components, while maintaining the quantitative and qualitative composition of all the other ingredients contained in the sea water.

Example

This example was used isoosmotic ionic solution selling GOEMAR under the brand PHYSIOMER®which consists of 100% undiluted does not contain sodium, sterile and preservative-free natural sea water, and other isoosmotic ionic solution, which consists of 100% sterile, potassium-enriched natural seawater sold GOEMAR under the brand SEROPHTA®.

The solution PHYSIOMER®used in this example contained in the vial, equipped with a tube for spraying (PHYSIOMER® Spray), or vial, equipped with a jet pulverizer (PHYSIOMER®Normal jet).

Solution (SEROPHTA®) contained in the vial, equipped with a tube for spraying (SEROPHTA®Spray).

The effectiveness of these isoosmotic ionic solutions was checked by conducting a study using a randomized group consisting of 350 children aged 6 to 10 years within 12 weeks.

Patients in the beginning of the experiment suffered from a cold or flu-like syndrome. Patients were divided into 4 homogeneous groups, which were subjected to the following treatment, respectively:

group 1: (PHYSIOMER®Normal jet),

group 2: (PHYSIOMER®Spray),

group 3: (SEROPHTA®Spray),

group 4: control group, without flushing the nasal cavity.

In groups 1 through 3 during 0-3 weeks ionic solution was injected six times a day and the following weeks were injected three times a day.

All patients in the four groups was examined by the doctor on the first day of the experience (visit 1), at the first-third week (visit 2) and at the sixth-eighth week (visit 3) and at week 12 (visit 4) after the start of the experiment.

Visit 1: diagnosis, selection for participation in the study, assessment of the severity of nasal symptoms, use of medication;

Visit 2: the study of health, the severity of nasal symptoms, possible changes in the types of medical drugs is s, evaluation of the effectiveness of treatment by the physician and patient assessment of the security;

Visit 3: health status - occurrence of relapse, evaluation of the effectiveness of treatment by the physician and patient assessment of the security;

Visit 4: final evaluation of the health status, the severity of nasal symptoms, evaluation of the effectiveness of treatment by the physician and patient assessment of the security.

Quantitative assessment of dry cough was conducted on a numerical scale as follows:

Dry coughNoLightModerateStrong
Score1234

The results are shown in table 1 below and shown in graphical form in Figure 1:

Table 1
Group 1Group 2Group 3Group 4
Visit 11,421,591,47 1,60
Visit 21,091,141,121,14
Visit 31,101,171,051,40
Visit 41,021,041,031,04

A noticeable difference between the patients of groups 1, 2 or 3 and patients of group 4 (control) was observed during the visit 3.

Quantitative assessment of nasal secretions was performed on a numeric scale as follows:

Nasal selectionNoLightModerateStrong
Score1234

The results are shown in table 2 below and shown in graphical form in Figure 2:

Table 2
/td> Group 1Group 2Group 3Group 4
Visit 12,582,842,832,70
Visit 21,76to 1.861,742,10
Visit 31,241,331,30to 1.86
Visit 41,201,241,231,55

A noticeable difference between the patients of groups 1, 2 or 3 and patients of group 4 (control) were observed during visit 2, visit 3 and visit 4.

Quantitative assessment of nasal secretions was performed on a numeric scale as follows:

3
Nasal selectionNoSerousSerous-purulentPurulent
Score124

The results are shown in table 3 below and shown in graphical form in Figure 3:

Table 3
Group 1Group 2Group 3Group 4
Visit 12,592,582,562,55
Visit 21,741,741,69to 2.06
Visit 41,161,231,231,53

During visits 2 and 4 there was a significant difference between naselenie secretions in children in groups 1, 2 or 3 and the children in the group 4.

The ability to breathe through the nose was assessed on a numerical scale as follows:

Breathing through the noseEasilyWith a small labourWith moderate difficulty Impossible
Score1234

The results are shown in table 4 below and shown in graphical form in Figure 4:

Table 4
Group 1Group 2Group 3Group 4
Visit 1of 2.262,242,272,16
Visit 21,271,281,201,58

Patients in groups 1, 2 and 3 there was an improvement in breathing through the nose, while patients in group 4 had only a small improvement. Nasal obstruction was assessed on a numerical scale as follows:

Nasal obstructionNoLightModerateStrong
Score1234

The results are shown in table 5 below and shown in graphical form in Figure 5:

Table 5
Group 1Group 2Group 3Group 4
Visit 31,161,241,211,64
Visit 41,101,121,171,39

During the visit 3 and visit 4 nasal obstruction in patients in group 4 (control) was expressed to a greater extent than patients in groups 1, 2 and 3.

Was prescribed medication, especially antipyretics, anti-infective funds, nasal protivozastojnye funds and mucolytics are presented.

The number of patients in each group who were assigned to receive antipyretics, was determined during each visit.

The results are shown in table 6 below and shown in the graphic is the Russian form in Figure 6.

Table 6
Group 1Group 2Group 3Group 4
Visit 126232124
Visit 2571113
Visit 3981133
Visit 485620

The number of patients in group 4 (control), taking antipyretics, during visits 3 and 4 was significantly longer than patients in groups 1, 2 and 3.

The number of patients in each group, which was appointed reception nasal protivozastojnye funds was determined during each visit.

The results are shown in table 7 below and shown in graphical form in Figure 7.

Table 7
Group 1Group 2Group 3Group 4
Visit 129273240
Visit 215141936
Visit 366347
Visit 447043

The number of patients in group 4 (control), taking nasal decongestants, during his visit 4 was significantly longer than patients in groups 1, 2 and 3.

The number of patients in each group who were assigned to receive anti-infective agents were determined during each visit.

The results are shown in table 8 below and shown in graphical form in Figure 8.

Table 8
Group 1Group 2Group 3Group 4
Visit 16125
Visit 27639
Visit 345721
Visit 46339

The number of patients systematically taking anti-infective funds in each group was very small. A statistically significant difference between patients in groups 1, 2 and 3 and the patients in group 4 were observed only during the visit 3.

The number of patients in each group, which was appointed reception mucolytics are presented that were determined during each visit.

The results are shown in table 9 below and shown in graphical form in Figure 9.

Table 9
Group 1Group 2Group 3Group 4
Visit 115141820
Visit 215152232
Visit 3991137
Visit 444624

Visit 2 showed that there was significant difference between patients in groups 1, 2 and 3 and the patients in group 4

The number of relapses of the disease was measured by determining the number of patients reporting the number of days when they feel sick during the stage of prevention, namely between 4 and 12 weeks, and by counting the days when children were not attending school due to ill health.

The number of children who were sick after the previous visit, are shown in table 10 below and shown in graphical form in Figure 10.

Table 10
Group 1Group 2Group 3Group 4
Visit 327353175
Visit 422222252

In the period between visit 2 and visit 3 75% of patients in group 4 were sick, that is about 60% higher than in groups 1, 2 and 3.

The number of children who missed at least one day of school after the previous visit, are shown in table 11 below and shown in graphical form in Figure 11.

Table 11
Group 1Group 2Group 3Group 4
Visit 1-253525350
Visit 316 142135
Visit 4781125

Patients in groups 1, 2 and 3 compared with patients in group 4 were observed 50-60%decrease in the number of days missed.

General health status of children in the beginning of the study and at the end of the study were evaluated by parents, then were assigned a score on a numerical scale as follows:

General healthExcellentGoodSatisfactoryPoor
Score1234

The results are shown in table 12 below and shown in graphical form in Figure 12.

Table 12
Group 1Group 2Group 3Group 4
Visit 12,482,422,432,45
Visit 41,431,541,552,16

At the end of the study the General health of the patients in groups 1, 2 and 3 was significantly better than the overall health of the patients in group 4.

The number of patients who had complications during the study are shown in table 13 below and shown in graphical form in Figure 13.

Table 13
Group 1Group 2Group 3Group 4
Visit 21041114
Visit 3871032
Visit 463314

Given the data above results we can conclude, what isoosmotic solutions in accordance with the invention are an effective solution for the prevention of complications from a cold. They provide rapid elimination of nasal symptoms, less use of medication, more rapid improvement in General health, as well as provide an opportunity to limit the number of missed school days.

1. The way to prevent complications from a cold or flu-like syndrome, which consists in the fact that isoosmotic ionic solution based on sea water with osmolarity equal to 250-350 mOsm/kg, is injected daily into each nostril for patients suffering from a cold or flu-like syndrome, from 2 to 9 times, preferably from 3 to 8 times, and more preferably from 4 to 6 times during the symptoms of cold or flu-like syndrome, and remission is administered 1 to 3 times daily in the form of a spray for at least two weeks, with the dose reduced in remission.

2. The method according to claim 1, in which the use isoosmotic ionic solution based on sea water with the following characteristics:
- pH 7,8-8,4;
the dry matter content equal to from 1 to 2% by weight;
- osmolarity equal to 250-350 mOsm/kg, preferably equal 305-315 mOsm/kg,
and contains the following main components:
- 500-2600 mg/l n is sodium (Na);
- 40-6500 mg/l potassium (Ka);
- 5800-6000 mg/l of chlorine ions (Cl);
- 20-400 mg/l calcium (Ca);
- 50-1500 mg/l magnesium (Mg).

3. The method according to claim 1 or claim 2, in which the use isoosmotic ionic solution based on sea water with the following characteristics:
- pH 7,8-8,4;
the dry matter content equal to from 1 to 2% by weight;
- osmolarity equal 305-315 mOsm/kg, and contains the following main chemical components:
- 2000-2600 mg/l sodium (Na);
40-80 mg/l potassium (Ka);
- 1200-1500 mg/l magnesium (Mg);
- 300-400 mg/l calcium (Ca);
- 5800-6000 mg/l of chlorine ions (Cl).

4. The method according to claim 1, in which the use isoosmotic ionic solution based on sea water with the following characteristics:
- pH 7,0-9,0;
the dry matter content equal to from 1 to 2% by weight;
- osmolarity equal to 250-350 mOsm/kg, and contains the following main chemical components:
- 500-1500 mg/l sodium, preferably 1000-1300 mg/l sodium (Na);
- 4500-6500 mg/l potassium, preferably 5000-6500 mg/l (Ka);
- 50-1300 mg/l magnesium, preferably 100-500 mg/l magnesium (Mg);
- 20-350 mg/l calcium, preferably 40-200 mg/l calcium (Ca);
- 4000-6000 mg/l of chlorine ions, preferably 4500-5000 mg/l of chlorine ions (Cl).

5. The method according to claim 1, wherein isoosmotic ionic solution on the basis of seawater contains additional bromine (Br), preferably in amounts of at least 50 mg/l, aluminum (Al), fluorine (F) iodine (I), iron (Fe), zinc (Zn), copper (Cu), manganese (Mn), selenium (Se).

6. The method according to claim 1, wherein in isoosmotic ionic solution based on marine water content of elements that differ from sodium, potassium, chloride ions, calcium and magnesium, is identical to seawater qualitatively and quantitatively.

7. The method according to claim 1, wherein the solution contains no preservatives or stabilizers.

8. The method according to claim 1, wherein the solution is administered year-round, preferably during epidemiological periods.

9. The method according to claim 1, wherein the solution is injected to the patients without the use of any of the agents selected from the group consisting of antibiotic, antipyretic, mucolytics, anti-inflammatory agents, anti-infective funds protivozastojnog nasal remedies, cough remedies and mixtures thereof.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics, namely to a composition for treating upper airways bacterial and viral infections and influenza. The composition contains benzophenantridine alkaloids, an aqueous-alcoholic extract of aboveground parts of Hippophae rhamnoides, a lipophilic extract of Echinacea angustifolia taken in certain amounts. Using benzophenantridine alkaloids, the aqueous-alcoholic extract of the aboveground parts of Hippophae rhamnoides, the lipophilic extract of Echinacea angustifolia in certain amounts in a combination for preparing oral compositions for treating the upper airways bacterial and viral diseases.

EFFECT: using the declared composition provides effective antiviral, antibacterial and anti-inflammatory action ensured by the synergetic effect.

9 cl, 1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: there are presented: a method for preventing or treating diseases caused by (+)RNA containing viruses of the genus Enterovirus or Flavivirus (the virus of the genus Enterovirus is specified in a group consisting of rhinoviruses and enterovirus type 71; the virus of the genus Flavivirus is specified in a group consisting of West Nile virus, dengue virus, tick-borne encephalitis virus, Saint Louis encephalitis virus, Murray Valley encephalitis virus and yellow fever virus) providing the use of an effective amount of glutaryl histamine or its pharmaceutically acceptable salt. There are also presented: a pharmaceutical composition for the above application and formulation, and a kit, the use of glutaryl histamine or its pharmaceutically acceptable salt for preparing the pharmaceutical composition for preventing or treating the diseases caused by (+)RNA containing viruses of the genus Enterovirus or Flavivirus. It has been shown that glutaryl histamine inhibited the dengue virus replication, provided the 40% death protection of the mice infected by tick-borne encephalitis virus (protective activity of ribavirin made 15%).

EFFECT: improved properties of the agent.

22 cl, 8 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to infectious diseases and immunology, and may be used for treating the patients with influenza and other influenza-like illnesses complicated with pneumonia. That is ensured by prescribing an antibacterial therapy and administering cytokine presented by interleukin-1β subcutaneously in a dose of 0.5…1.0 mcg, and then cytoflavin immediately after cytokine intravenously drop-by-drop in a dose of 5…10 ml once a day for four days.

EFFECT: method enables reducing the length of the clinical manifestations of influenza and influenza-like illnesses complicated with pneumonia, and forming protective immunity ensured by lowering the concentration of the anti-inflammatory cytokines and increasing blood serum circulating interferons with reducing side effects.

1 dwg, 7 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: invention relates to field of biotechnology. Described is molecule of chimeric nucleic acid of porcine circovirus (PCV2Gen-1Rep), which includes molecule of nucleic acid, coding porcine circovirus of type II (PCV2), which contains sequence of nucleic acid, coding protein Rep of porcine circovirus of type 1 (PCV1). Chimeric molecule of nucleic acid is constructed by replacement of gene Rep ORF1 PCV2 with gene Rep ORF1 PCV1. Invention also includes biologically functional plasmid or viral vector, which contain unique molecules of chimeric nucleic acids, suitable host cells, transformed by plasmid or vector, infectious chimeric porcine circoviruses, which produce suitable host cells, method of obtaining immunogenic polypeptide product with application of novel chimera, viral vaccines, protecting pig against viral infection or syndrome of postweaning multisystem wasting syndrome (PMWS), caused by PCV2, methods of protecting pigs against viral infection or postweaning multisystem wasting syndrome (PMWS), caused by PCV2, methods of obtaining unique chimera PCV2Gen-1Rep and the like. Invention can be applied in veterinary.

EFFECT: invention additionally includes novel method of increasing level of replication and PCV2 titre in cell culture.

21 cl, 2 dwg, 6 ex

FIELD: medicine.

SUBSTANCE: what is administered is a combined therapeutic agent containing an activated potentiated form of human gamma-interferon (IFN-γ) antibodies, an activated potentiated form of CD4 receptor antibodies and an activated potentiated form of histamine antibodies.

EFFECT: effective treatment of the various types of influenza ensured by potentiating the antiviral activity of the activated potentiated gamma-interferon antibodies.

12 cl, 5 tbl, 1 dwg, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to veterinary science and medicine. What is presented is a method of treating avian influenza A/H5N1 using high-polymer yeast RNA. A drug preparation is presented by a soapy amphiphilic one-chain high-polymer RNA of Saccharomyces cerevisiae recovered from dry baker's yeast with alkali titrated oleic acid or sodium dodecyl sulphate by treating recovered RNA in oleic acid.

EFFECT: invention provides the high-effective anti-influenza drug containing a natural interferon inducer.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present group of inventions refers to medicine, namely therapy and gastroenterology, and concerns treating functional gastrointestinal disturbances. That is ensured by administering a composition containing activated potentiated histamine, tumour necrosis factor alpha (TNF-α) and brain-specific protein S-100 antibodies.

EFFECT: administering such composition provides treating irritable bowel syndrome and other functional gastrointestinal disturbances ensured by normalising the motor-evacuation function of the large intestine.

12 cl, 4 ex, 4 tbl

FIELD: medicine.

SUBSTANCE: present group of inventions refers to medicine, namely to therapy, and concerns treating infectious diseases caused by an influenza virus with type H5N1 surface antigen. That is ensured by administering a therapeutic agent containing a homeopathic activated potentiated form of the human gamma-interferon antibodies prepared of a matrix solution of affine purified human gamma-interferon antibodies in the concentration of 0.3-5.0 mg/ml.

EFFECT: higher clinical effectiveness in the infectious diseases.

8 cl, 2 ex, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a combined preparation for influenza and acute respiratory viral infections. As active substances, the declared preparation contains paracetamol 100-400 mg, phenylephrine hydrochloride 10 mg, pheniramine maleate 20 mg, and tilorone hydrochloride 20-60 mg.

EFFECT: combined preparation has antiviral, immunostimulating, anti-inflammatorry and antipyretic action, enhances the interferonogenic and antiviral effect of tilorone and the antipyretic and anti-inflammatory effect of paracetamol.

2 cl, 3 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine. An antiviral agent is used by individuals having sensitive face skin, inactivates viruses, such as norovirus and influenza virus, and has the excellent bactericidal properties. The antiviral agent wherein the percentage of total laurate soap and myristate soap makes 70 wt % or more at total soaps with saturated fatty acids, and the percentage of stearate soap and the percentage of palmitate soap makes less than 15 wt % at total soaps with saturated fatty acids, and the percentage of oleate soap making 50 to 75 wt % of total soaps. The group of inventions disclosed a detergent causing no environmental pollution, as it is easily degraded in the natural environment.

EFFECT: group of inventions provides inactivating the virus with the very low concentration of the agent, causes no eczema and allergic dermatitis.

5 cl, 3 tbl, 15 dwg, 11 ex

FIELD: medicine.

SUBSTANCE: method involves a dietary therapy, taking mineral water in an amount of 100-150 ml, 3 times a day and exposure to a physical factor. What is used is the Pevzner's diet No. 5. Karachinskaya chloride-hydrocarbonate sodium gas-free mineral water of total mineralisation up to 3 g/dm3, at a temperature of 38-40°C is taken 30-40 minutes before a meal. The physical factor represents a magnetic laser therapy and an EHF therapy. The contact magnetic laser therapy covers three zones sequentially at a frequency of 5 Hz: an epigastric zone and the right and left upper hypochondria along the midclavicular lines, for 4 minutes for each zone within the course of 10 procedures. The EHF therapy involves combined exposure on two projection zones: in the right hypochondrium and on the sternum generated by a broadband noise emitter at an emission frequency of 40-63 GHz, for 20 minutes, every day within the course of 10 procedures.

EFFECT: method provides more effective rehabilitation treatment following endoscopic cholecystectomy ensured by the early integrated therapeutic exposure.

2 ex, 4 tbl

FIELD: medicine.

SUBSTANCE: method involves the intake of low-mineralised low-carbonate sulphate-hydrocarbonate sodium-calcium mineral water of Slavyanovskiy source. The mineral water is taken 45 minutes before meals, in a dose of 3.3 g/kg of body weight per one intake, 3 times a day. That is combined with a partial-load physical activity, dietary therapy No. 5, mineral baths with the above mineral water at temperature 36-37°C, for 15 minutes, every second day; the therapeutic course involves 10 procedures; that is also combined with a dynamic electrical nerve stimulation (DENS) according to the schedule. The therapeutic exposure is segmental at frequency 7710 Hz for 10 minutes. The therapeutic exposure covers a projection of a liver at frequency 10 Hz for 5-10 minutes. The therapeutic exposure covers a projection of a pancreatic gland 77 Hz for 10 minutes and biologically active points (BAPs) GI-4(He Gu) and RP(sang-yin-jiao). The BAP exposure with programmed minimum effective dose (MED) is alternated every second day. The therapeutic course is 10 procedures.

EFFECT: method provides relieving pain and dyspeptic syndrome, improving the functional status of the pancreatic gland, regulating the digestion process and stimulating the adaptive reserves.

3 ex, 4 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely gynaecology, physiotherapy. A method involves the integrated treatment of the patients with genital endometriosis and hysteromyoma. The treatment involves taking mineral water, observing a biologically programmed light pattern, taking radon baths and radon gynaecological irrigations and small enemas, as well as conducting a laser therapy of biologically active points (BAPs). The patients take carbonated chloride-hydrocarbonate-sulphate sodium-calcium warm Narzan water taken from sources No. 4, No. 7 and No. 24, 3.4 mg per kg 3 times ad day, 40 minutes before meals. The radon baths are taken with the radon concentration of 1.5 kBq/l. The radon gynaecological irrigations and microenemas are performed with the radon concentration of 6.5 kBq/l, temperature 36°C, for 15 minutes within the course of 10-12 procedures. The BAP laser therapy is conducted in an autoresonant mode. The BAPs of anterior median meridian are covered, including: 1-2 (qu-gu), 1-3 (zhong-ji), 1-4 (guan-yuan), 1-5 (shi-men), 1-7 (yin-jiao); renal meridian: R-12 (da-ho), R-13 (qi-xu), R-14 (si-man), R-15 (zhong-zhu), R-16 (huang-shu); bladder meridian: V-31 (shang-liao), V-32 (ci-liao), V-33 (zhong-liao), V-34 (xia-liao); posterior median meridian: T-2 (yao-shu), T-3 (yao-yang-guan), T-4 (min-man), T-5 (xuan-shu). Using the radon baths of the different radon concentrations 'softens' an effect of the absorbed radiation dose on the homeostasis systems and preserves an effect of a high absorbed dose on the genital system. The laser therapy in the autoresonant mode within pathological BAPs improves the accuracy of the exposure on the pathological processes within a target organs.

EFFECT: method prolongs the remission, normalises the hormonal ratios in the remote period.

2 dwg, 4 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to physiotherapy, balneotherapy. Taking baths is realised. Bath includes gas-saturated water, and beer. Saturation with gas is performed by addition of fresh non-filtered beer in ratio 1:10 and supply of air, heated to 25°C from bottom to top. 1/2 part of water, heated to 40°C is poured into bathtub. After that, beer is added and then water, heated to 40°C, in amount of remaining 1/2 part. Bathtub is made from oak with holes.

EFFECT: method increases efficiency of bath realisation due to complex impact on organism with thermal and chemical factors and aeromassage.

FIELD: medicine.

SUBSTANCE: invention refers to medicine, and aims at treating irritable bowel syndrome with diarrhoea. What is used is a low-mineralised sodium hydrocarbonate Abalakhskaya mineral water (AMW) with an faintly alkaline reaction of aqueous medium. The complex therapeutic course makes 21 days including drinking therapy - 18 days, a single drinking dose of AMW of temperature 38-40°C is gradually increased from 50-80 ml to 180-200 ml; the procedures of duodenal drainage are performed with the use of AMW of temperature 37-38°C in the amount of 200 ml of a single dose; for the procedures of intestinal irrigations, AMW is pre-heated to 40-42°C, while a single dose makes 500 ml gradually increased to 800 ml; the procedures of intestinal irrigations are alternated with baths.

EFFECT: method provides higher clinical effectiveness in irritable bowel syndrome, normalised intestinal motility.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely rehabilitation medicine, physiotherapy and urology and may be used for the purpose of rehabilitation of the patients suffering urolithiasis following lithitripsy. That is ensured by the intake of the herbal tea "Veres" containing wild camomile blossom, knotgrass herb, nosebleed herb and horsetail herb, juniper fruits, sage leaves, birch leaves, red bilberry leaves, linseeds taken in equal proportions. The infusion is taken in a dose of 100 ml 3 times a day 30 minutes before meals for 5-7 preoperative days. The common background therapy follows the lithotripsy procedure. That is combined with the additional intake of the herbal tea "Veres" for 10 days following the above procedure and hydrocarbonate sulphate calcium-magnesium mineral water "Kazachinskaya" of mineralisation 1.44g/l for 24 days following lithotripsy. The mineral water "Kazachinskaya" is taken in a dose of 200-250 ml 3 times a day before meals. Further, after the lithotripsy procedure, a projection of the involved kidneys and renal duct is exposed to the apparatus Bemer-3000 at AC field frequency 30-1000 Hz and magnetic field intensity 8.5-100 mcT. The exposure is generated by an intensive contact applicator from 2 fields in the mode-1 (2-4 stages) of 8 minutes. The therapeutic course makes 10 daily procedures. The background therapy is followed by another one-month intake of the herbal tea "Veres", as well as by another exposure to the apparatus "Bemer-3000" at the same parameters of the electromagnetic field. The contact exposure also covers the kidneys and the lower one-third of the renal duct by means of the intensive application from 2-4 fields in the mode-2 (2-4 stages) of 12 minutes. The exposure is daily, two times a day.

EFFECT: method provides reducing the length of calculus fragments discharge following the lithotripsy procedure, improving the clinical and biochemical blood and urine statuses, renal blood flow, treating and preventing the postoperative complications, recovering the immunological responsiveness and antioxidant protection.

4 dwg, 3 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to gastroenterology and represents a method of treating irritable bowel syndrome with constipations with using low-mineralised hydrocarbonate sodium mineral water "Alabakhskaya" (AMW) with a faintly alkaline reaction of the aqueous medium involving the daily three-time drinking of AMW, duodenal drainages with using AMW, intestinal irrigations with using AMW following cleansing enemas, taking toning pine or salt-water baths; the integrated therapeutic course makes 21 day, including an 18-day drinking therapy, a single drinking dose of AMW at temperature 36-38°C is gradually increased from 50-80 ml to 200 ml; the duodenal drainage is conducted with using AMW at temperature 37-39°C in the amount of 200 ml of a single dose; for intestinal irrigations, AMW is pre-heated to 39-40°C, while a single dose makes 500 ml to be gradually increased to 800 ml; the intestinal irrigations are alternated with taking baths.

EFFECT: invention provides higher clinical effectiveness and reduces the length of treatment of irritable bowel syndrome with constipations.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and aims at treating bile passage dysfunction. What is involved is a 2-staged integrated treatment. At the 1st stage, a diet, sorbents, mineral water, physiotherapy (thermal vibromassage of the area of the gall bladder and liver, or biologically active points) are prescribed. At the 2nd stage, the treatment is prolonged by administering adsorbents in the form of herbal preparations, as well as pelotherapy considering a type of dysfunction.

EFFECT: method enables reducing the length of pain management, prolonging remission or achieving full rehabilitation in children and adolescents suffering bile passage dysfunction and living in environmentally unfriendly regions.

3 cl, 4 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to physiotherapy, gastroenterology. The method involves dietary therapy No. 5, general pine baths, magnetic laser therapy, intake of mineral water with underlying sparing training regimen followed by transverse galvanisation of the epigastrial area. The transverse galvanisation immediately follows the intake of mineral water between 10 to 11 o'clock. Additionally, the right hypochondrium and sternum are exposed to EHF radiation generated by a broadband noise transducer with a frequency of 40-63 GHz, for 10 minutes per each area, every day; the therapeutic course is 10-12 procedures.

EFFECT: method enables higher clinical effectiveness ensured by using a chronobiological approach to treating the patients for the purpose of relieving the functional disorders of the bile system with underlying increased adaptive capacities of the body.

2 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely - to dermatology, physiotherapy. The method includes taking mineral baths with mineral water of Annensk deposit of the Khabarovsk Territory and joint mud therapy. Additional, the patient intakes mineral water 100 - 200 ml, 3 times a day 30 minutes before meals. The baths are taken once a day at temperature 37 - 38°C, for 10-20 minutes. The therapeutic course includes 10-14 baths. The joint mud therapy is performed by applying low-mineralised low-sulphide silt mud on the affected joints. The mud therapy is performed two days running with a one-day pause. The therapeutic course is 6-10 procedures. After the therapeutic course is completed, the affected joints are coated with Relyct gel for 1.0 - 1.5 months dissolved in mineral water.

EFFECT: method prolongs the length of the intercurrent period.

3 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely therapeutic dentistry and may be used for treating destructive forms of chronic periodontitis. That is ensured by administering a therapeutic preparation into a root canal. A sonic phoresis of the therapeutic preparation Beresh plus drops is preceded by coating the skin surrounding a causative tooth with a therapeutic mixture containing the preparation Beresh plus drops, 10% calcium gluconate and Vaseline oil. Thereafter, an emitter is used to process the area. The sonic phoresis is followed by a root canal obturation with calcium hydroxide. That is combined with administering ascorbic acid in a daily dose of 50-100 mg and the preparation Beresh plus drops 1 drop per 2 kg of body weight a day orally. The therapeutic course is 5-8 procedures.

EFFECT: invention enables arresting the inflammatory process in the aggressive lesion, reducing the number of complications and aggravations ensured by accelerating the repair processes in the apical aggressive lesion.

2 dwg

Up!